Calmare Therapeutics Inc (OTC:CTTC)

Reasons for tracking:

•  Appears the company has resolved the legal issue that had hampered its ability it to market one of its products  (Calmare® Pain Device) in certain markets.

“Proactively address the 70% loss in gross revenues from $3.33 million in 2010 to $913,000 in 2011, which were largely attributed to the terms of the Amendment that did not allow the Company to sell in the EMENA territory -- a global territory which was prospected and developed by CTI funds and salespersons -- and unduly limited CTI sales to the Americas and Oceana;”

• Furthermore, the company appears to be in position to possibly receive FDA approval for its products.  One of the Boards initiatives is to:

 “...successfully attain U. S. Food and Drug Administration (the "FDA") approval for the Calmare® Pain Device, which the Amendment expressly prohibited without the prior consent of certain non-FDA bona fide professionals.”

• The last time this company reported revenues in excess of $3 million, shares reached a high of $1.80. Management stated:

"CTI is prepared to regain its prior revenue footholds while establishing new ones in the global medical device marketplace," said CTI President & CEO Conrad Mir.  "This initiative is paramount in the future success of CTI, which may result in greater revenues and attaining the long-awaited FDA product approval. “

 Caveats :

• We need to peruse SEC filings to determine if the company has any other unresolved legal issues.